Multiple peer-reviewed publications have consistently demonstrated a set of blood-based protein biomarkers associated with idiopathic pulmonary fibrosis (IPF) disease progression. A set of well-qualified assays suitable for use as prognostic or predictive biomarkers within the context for IPF clinical trials is lacking. In collaboration with the Prognostic Lung Fibrosis Consortium (PROLIFIC), Rules-Based Medicine, a Q² Solutions Company, developed highly optimized and analytically validated blood-based proteomic assays for IPF on the Luminex^® multi-analyte profile (MAP), specifically focusing on the most relevant IPF biomarkers related to epithelial damage, fibrosis, inflammation and thrombosis.

Complete the form to access this whitepaper